• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Beyond the codes: The power of clinical notes in Truveta Data

Beyond the codes: The power of clinical notes in Truveta Data

by Truveta staff | Jan 9, 2025 | Data

In the world of medical research, data drives discovery. But until recently, nearly 80% of data relevant to research has been hidden in clinical notes. These notes include detailed observations, symptoms, and treatment plans that are absent from the structured data...
Combating respiratory viruses with EHR data: Key use cases for life sciences and public health

Combating respiratory viruses with EHR data: Key use cases for life sciences and public health

by Truveta staff | Dec 10, 2024 | Data

“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity Health  Electronic health record (EHR) data is rapidly changing how life sciences,...
A year later: New GLP-1 clinical trial results validate Truveta’s real-world data study

A year later: New GLP-1 clinical trial results validate Truveta’s real-world data study

by Truveta staff | Dec 6, 2024 | Data

New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
How real-world data is transforming GLP-1 research for diabetes and obesity care

How real-world data is transforming GLP-1 research for diabetes and obesity care

by Truveta staff | Nov 7, 2024 | Data

GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. First discovered forty years ago, GLP-1 receptor agonists were initially approved for type 2 diabetes in 2005, with the first weight-loss-specific approval following in 2014. Flash...
Advancing orthopedics: How device-level data is shaping the future of knee, hip, and shoulder replacements

Advancing orthopedics: How device-level data is shaping the future of knee, hip, and shoulder replacements

by Truveta staff | Oct 10, 2024 | Data

The US market size for joint replacement is projected to balloon to nearly $38 billion by 2030, nearly doubling its 2022 value. The combination of an aging population, increasing rates of osteoarthritis and obesity, along with advancing technology, are all...
Top 10 reasons to choose Truveta’s mother-child EHR dataset

Top 10 reasons to choose Truveta’s mother-child EHR dataset

by Truveta staff | Sep 13, 2024 | Data

Mother and child health are inherently interconnected, offering unique insights into how maternal health, behaviors, and exposures impact child outcomes. Unfortunately, the potential of this data has historically been limited by challenges in data collection, the long...
« Older Entries
Next Entries »

Share this


Recent posts

  • Truveta experts: Gestational diabetes screening in real-world practice
  • Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
  • Johns Hopkins builds research community to explore new frontiers in health using Truveta Data

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.